Skip to main content »

Trinity College Dublin

A New Concept For Transcatheter Mitral Valve Replacement

MiVaR

©Copyright by Trinity College Dublin 2013, All Rights Reserved.

The Product

Our MiVaRTM device focuses on the treatment of mitral regurgitation (MR), which is the most common heart valve disease. Early-stage symptoms can be treated with medication, however as the disease becomes more severe, patients require interventional treatment in the form of mitral valve replacement or repair.

Currently the gold-standard treatment for MR is an open-chest/open-heart operation. This surgical treatment is inherently risky, especially with an elderly patient cohort. It is estimated that half of the patients which present with MR are denied surgery due to the high risk associated with open-heart procedures. The development of less-invasive alternatives to this surgical treatment would address this unmet clinical need.

A number of companies are developing transcatheter devices to service this need, and a sub-segment of these companies are focused on mitral valve replacement. To date, no company has achieved clinical success in this area. The MiVaRTM team is developing a new approach to transcatheter mitral valve replacement; this catheter based approach replaces the dysfunctional native mitral valve using a transapical delivery system.


For more information contact:

Principal Investigator
Dr Bruce Murphy, Ph.D.
Email: bruce.murphy@tcd.ie
Tel: +353 1 896 8503

Technology Transfer Case Manager
Dr Gordon Elliott, Ph.D.
Email: gordon.elliott@tcd.ie
Tel: +353 1 896 4151

This research program is funded by Enterprise Ireland’s Commercialisation fund.

Page last modified on February 18, 2014
© 2008-2017 Neural Engineering Group - Trinity College Dublin